Premature Menopause in Patients with BRCA1 Gene Mutation

@article{Rzepkagrska2006PrematureMI,
  title={Premature Menopause in Patients with BRCA1 Gene Mutation},
  author={I. Rzepka-g{\'o}rska and B Tarnowski and Anita Chudecka-Głaz and Bohdan G{\'o}rski and Dorota Zielińska and Aleksandra Tołoczko-Grabarek},
  journal={Breast Cancer Research and Treatment},
  year={2006},
  volume={100},
  pages={59-63}
}
This study was undertaken with regard to the gonadotropin theory of ovarian cancer advocated in the literature and was designed to disclose specific features of ovarian morphology in carriers of the BRCA1 gene mutation. We enrolled 171 patients and divided them into two groups: A (n=90)—operated for breast cancer (30 patients with and 60 without the BRCA1 mutation); B (n=81)—with the BRCA1 mutation qualified for preventive adnexectomy. According to the authors’ classification described herein… Expand
View on Springer
ncbi.nlm.nih.gov
98 Citations
Highly Influential Citations
2
Background Citations
26
Methods Citations
1
Results Citations
4

98 Citations

Citation Type

Citation Type

Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation.
TLDR
Women who carry a BRCA mutation experience menopause earlier, on average, than women who do not have a mutation, but the difference is small and does not appear to affect fertility. Expand
Fertility and Pregnancy Counseling of Breast Cancer Patients with Germline BRCA Mutations
TLDR
Based on both the unique features and needs of these patients as well as the limited evidence on the performance of fertility preservation strategies and on the safety of having a pregnancy following the end of anticancer treatments, oncofertility counseling is particularly complex in young women with newly diagnosed BRCA-mutated breast cancer. Expand
Association of BRCA Mutations and Anti-müllerian Hormone Level in Young Breast Cancer Patients
TLDR
Fertility preservation should be considered more aggressively in young breast cancer patients with BRCA mutation, particularly in young, reproductive-aged patients with breast cancer who have significantly lower serum AMH level. Expand
Do BRCA1/2 mutation carriers have an earlier onset of natural menopause?
TLDR
Various types of selection bias hamper the comparison of ANM between BRCA1/2 mutation carriers and noncarriers, genetically tested in the clinic. Expand
BRCA1 germline mutations may be associated with reduced ovarian reserve.
TLDR
BRCA1 carriers have lower age- and BMI-adjusted serum AMH levels compared with women without BRCA mutations, and this results contribute to the current body of literature regarding BRCa carriers and their reproductive outcomes. Expand
Ovarian reserve of women with and without BRCA pathogenic variants: A systematic review and meta-analysis
TLDR
This meta-analysis evaluates whether women carrying BRCA mutations (BRCAm) have decreased ovarian reserve, in terms of Anti-Muellerian Hormone (AMH), compared to women without BRCAm (wild-type) to find a trend of reduced AMH level. Expand
Influence of BRCA Mutations on the Reproductive Potential of Women. A Systematic Review
TLDR
The review of the literature does not show differences when evaluating the response of BRCA carriers to an ovarian stimulation protocol, and the revision seems to show slight differences in the ovarian reserve. Expand
Premature ovarian aging in BRCA carriers: a prototype of systemic precocious aging?
TLDR
The results suggest a link between BRCA mutation, accelerated ovarian aging and systemic aging-related pathophysiology. Expand
Effects of BRCA gene mutation on female reproductive potential: A systematic review.
TLDR
In conclusion, there is no compelling evidence indicating that the rate of nulliparity, serum AMH, antral follicle counts and ovarian response are affected in BRCA mutation carriers. Expand
[Breast and ovarian cancer due to BRCA1&2 hereditary cancer predisposition syndrome and reproduction: literature review].
TLDR
Pregnancy and lactation have no effect on breast and ovaries or even decreases the risk, and infertility treatments do not increase breast and ovarian risk, according to a review of the international literature from the PubMed database. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 24 REFERENCES
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
TLDR
Bilateral prophylactic oophorectomy reduces the risk of coelomic epithelial cancer and breast cancer in women with BRCA1 or BRCa2 mutations. Expand
Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers.
TLDR
Bilateral prophylactic oophorectomy is associated with a reduced breast cancer risk in women who carry a BRCA1 mutation, and the likely mechanism is reduction of ovarian hormone exposure. Expand
Attitudes toward preventive oophorectomy among BRCA1 mutation carriers in Poland.
TLDR
Patient acceptance of preventive oophorectomy is acceptable to most Polish women at high risk of hereditary ovarian cancer and should be among the range of services offered in cancer genetics clinics. Expand
High follicular phase luteinizing hormone levels in young healthy BRCA1 mutation carriers: implications for breast and ovarian cancer risk.
TLDR
Confirmatory studies are warranted to establish whether elevated LH levels are part of the BRCA1 phenotype and may be manipulated in order to reduce cancer risks in BRCa1 mutation carriers. Expand
Efficacy of Risk‐Reducing Salpingo‐Oophorectomy in Women with BRCA‐1 and BRCA‐2 Mutations
TLDR
Prophylactic bilateral salpingo‐oophorectomy can be regarded as an effective risk‐reducing procedure that permits early diagnosis of ovarian cancer at the time of surgery and significantly reduces the risk of breast and ovarian cancer in women with germ‐line mutations in the BRCA‐1 and BRCa‐2 genes. Expand
Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer.
TLDR
The study group consisted of 66 Polish families with cancer who have at least three related females affected with breast or ovarian cancer and who had cancer diagnosed, in at least one of the three affected females, at age <50 years. Expand
Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
TLDR
Except for the possible biological significance of surface micropapillae on ovaries from BRCA1 and BRCa2 mutation carriers, there is no histologic evidence for a genetically determined ovarian carcinoma precursor lesion. Expand
A high proportion of founder BRCA1 mutations in Polish breast cancer families
TLDR
The findings suggest that a rapid and inexpensive assay directed at identifying the 3 common founder mutations will have a sensitivity of 86% compared to a much more costly and labor‐intensive full‐sequence analysis of both genes. Expand
Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
  • T. Rebbeck, T. Friebel, +16 authors B. Weber
  • Medicine, Mathematics
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
TLDR
Short-term HRT use does not negate the protective effect of BPO on subsequent breast cancer risk in BRCA1/2 mutation carriers, and HRT of any type after BPO did not significantly alter the reduction in breast cancerrisk associated with BPO. Expand
Risks of cancer in BRCA1-mutation carriers
TLDR
Estimates of breast and ovarian cancer risks are provided which are useful for counselling BRCA1-mutation carriers and carriers are at increased risk of colon and prostate cancer, which may be of clinical significance in certain families if the risks are associated with specific mutations. Expand
...
1
2
3
...